Hyaluronic acid (HA), an unbranched high molecular weight polysaccharide can now be measured by several immunometric assays. The connective tissues are the main source of HA and it is destroyed mainly in the liver. Very high levels of HA occur in mesothelioma, Wilms' tumour and acute liver failure, and moderate increases in rheumatoid diseases, renal failure and cirrhosis. Local increased production of HA is a feature of several forms of lung disease. HA is an indicator of connective tissue turnover, of the function of the receptor mechanisms for its capture and destruction by the liver, and of the removal of low molecular weight fragments by the kidney.
Connective tissues are rich in proteoglycans which are made up ofpolysaceharide and protein units in a ratio of approximately 19: I. These very large polyanions bind water and cations and form the ground substance of connective tissue. Proteoglycans are also present within cells and on their surfaces. The polysaccharide chains of proteoglycans are glycosaminoglycans (GAG), previously known as mucopolysaceharides, the polysaccharide units containing a derivative of an amino sugar either glucosamine or galactosamine. At least one sugar in the pair has a negatively charged carboxylate or sulphate group. Hyaluronate, chondroitin sulphate, keratan sulphate, heparan sulphate and heparin are the major glycosaminoglycans. In the proteo glycan from cartilage keratan sulphate (Nacetylglucosamine, galactose polymer) and chondroitin sulphate (N-acetylglucosamine, glucoronic acid polymer) are covalently attached to a protein backbone. These subunits are then joined to a very long filament of hyaluronate through a link protein, resulting in a structure with a molecular weight of some 200-300 million. Dye binding assays are used for the estimation of total GAGs, and have shown the serum concentration to be in the region of 200 mg/LY The investigation of urinary GAG excretion is an important investigation in inborn errors of GAGs such as Hurler's and Hunter's syndromes Correspondence: Prof. E H Cooper. 444 and Morquio's disease.l" This group of diseases has previously been known as the mucopolysaccharidoses. The results of these earlier studies, whilst showing the broad patterns of disturbance of GAG levels and excretion in disease, used methods that lacked precision as judged by the marked differences between controls and from one investigator to another.
Research into the biochemistry, immunology and pathophysiology of cartilage and connective tissue has greatly expanded knowledge of the proteoglycans during the past decade. In parallel with an improved understanding of the structure and biophysics of cartilage has been the recent development of specific assay methods for cartilage proteoglycans and their breakdown products in synovial fluid and serum."" These assays have been of immense value in the study of local perturbations in GAG production and destruction in diseases of bone, joint and soft tissues; for example using an ELISA the serum keratan sulphate has been shown to be 261 ± 51 mg/L in controls and rises to 475 ± 178 mg/L in osteoarthritis" .(see Lohmander'? for review).
The development of immunometric assays for hyaluronic acid (HA) (also called hyaluronate and hyaluronan), has focused attention on this particular glycosaminoglycan and has shown that its concentration in body fluids is affected by many factors. Furthermore, the measurement of HA concentration in various in body fluids can reflect a wide range of diseases, outside the confines of bone and joint disorders, that affect its production and catabolism. I I
MEASUREMENT OF HYALURONIC ACID
Earlier methods from the assay of serum HA have often .used multistep procedures. The first step has usually been to precipitate the total GAGs with cetyl pyridinium chloride. 12 The precipitate is then redissolved and the GAGs separated by electrophoresis with the individual components quantified by densitometry." An alternative procedure has been to measure the cetyl pyridinium complexes by nephelometry before and after digestion with Streptomyces hyaluronidase." HPLC techniques have been described for the measurement HA. 15
• 16
The development of radioimmunometric assays has lead to a great increase in information about HA in health and disease. These assays have been based on the isolation of binding proteins for HA from bovine cartilage" and human brain, called hyaluronectin (HN). IIi. the assay developed by Laurent and Tengblad'! bovine cartilage HA binding protein (labelled with 1 125 ) is incubated with varying amounts of free HA and a fixed amount of HA bound to Sepharose gel. The binding protein is allowed to partition between free and bound polysaccharide. The amount of radioactivity pelleted with the gel is a function of the amount of free HA in the sample. This assay has been developed into a commercial assay by Pharmacia AB, Sweden," with a working range of 4-500 J1g/L and a CV of about 10%.
Delpech et al. 2o have described an enzymelinked immunosorbent assay using microtitre plates coated with HA, exploiting the inhibition of HN binding by soluble HA. The HN bound to the plate is revealed by alkaline phosphataseconjugated anti-HN antibodies. This assay and that of Pharmacia" both detect high molecular weight HA as well as its lower molecular weight fragments. A recent ELISA method takes advantage of an antikeratin sulphate antibody to differentiate between coated aggregating rat chrondrosarcoma proteoglycan, which captures the hyaluronate, and keratin sulphate-bearing aggregating proteoglycan added subsequently. The range of this assay was linear to the logarithmic concentration of hyaluronate in the range of l5-l000mg/L, and only measures HA > 10000 J1g/L molecular weight. 21 Another ELISA has been described which depends on the specific binding of HA to the hyaluronic acid binding region (HABR) of proteoglycan (PR). The remaining uncomplexed PG monomers were determined by incubation with specific monoclonal antibodies to HABR followed by addition of polyclonal antibodies against PG monomers and enzyme-conjugated antibodies. The HA in the samples were quantitated by their inhibitory capacity in the assay." All these recent assays show close agreement with the Pharmacia commercial assay.
Physiology of HA production and catabolism HA is an unbranched polysaccharide built from repeating disaccharide units of D-glucuronic acid and N-acetyl D-glucosamine linked by B(I-3) and B(1-4) glycosidic linkages, respectively. The polymer is multidisperse with its main component in the range of 400-1000 kda." It is synthesized by a unique mechanism associated with the plasma membrane whereby the HA chain grows at the reducing end by the alternate addition of UDP-hyaluronate to the substrates UDP-N-acetylglucosamine and UDP-glucuronic acid." The main sites of production are the connective tissue and synovial membranes; HA forms an important component of the tissue ground substance reacting with fibronectin, other GAGs and collagen, with the cytoskeleton and with specific cell-surface binding proteins. 25 ,26 Hyaluronic acid diffuses from the tissues and joint fluid to enter the circulation via the lymph" to give a concentration in the blood of 10-100J1gL, with a mean of 30 to 40 J1g/L, as measured immunochemically; non-irnmunochemical assays are either insensitive to the normal low serum HA concentraation or have reported considerably higher values." The HA level tends to increase with age, although levels in young children have been reported to be 59 ± 27 J1g/L. 17 Hyaluronic acid is cleared rapidly from the blood mainly as the result of its uptake by receptors on hepatic endothelial cells; studies in man using labelled HA have shown a half life of 2,5-5,5 min. Whole body autoradiographic examination of mice indicates that the spleen and lymph nodes are also sites of concentration of injected HA 28 possibly involving the reticulo-endothelial system. The liver receptors show a high affinity for the high molecular weight HA species. The kidney filters and partially catabolizes low molecular weight HAs and this mechanism is thought to contribute < I % to the total HA clearance per day. The mean (± SD) urinary excretion on 22 normal subjects was 33 (± 77) J.lg/24 h. However, urinary excretion tends to rise in diseases associated with increased serum HA levels." Serum HA shows a rise in level after rising out of bed in the morning but otherwise is stable."
A number of immune regulatory functions are associated with hyaluronic acid, notably its effect on T cells" and in tum its production rate is stimulated by cytokines, notably ILl, IL6 and tumour necrosis factor.'! In this respect it is interesting that high levels of serum HA occur in septicaemia." However, although the levels of HA can transiently be raised by several orders of magnitude in acute liver disease no syndromes have been causally related to high levels of HA, with the rare exception of coagulation defects and hyperviscosity seen in a few cases of Wilms' tumour where the concentration rises to a point when the viscoelastic properties of HA alter the rheological behaviour of the blood." The molecular weight of HA influences its action on target tissues, for example partially degraded HA stimulates angiogenesis in vivo. 34 
CLINICAL APPLICAnONS OF HA ANALYSIS
The introduction of immunologically based assays has enabled serum and urinary HA levels to be studied in a wide spectrum of diseases. The new wave of clinical interest in this analyte has been pioneered by Laurent and her associated clinicians in the University ofUppsala. However, the recent introduction of the commercial HA-RIA has already been followed by independent reports on the pathophysiology of HA. Several areas have been investigated so far, the main clinical applications at present are related to liver disease, chronic renal failure, rheumatology and some forms of neoplastic disease, other disorders such as respiratory disease are still at an early stage of investigation.
Neoplastic diseases
Mesothelioma It is recognized that increased blood and pleural fluid HA levels can occur in mesothelioma, a tumour arising in the pleural epithelium usually as the consequence of the inhalation of asbestos. It has been reported that HA was virtually the only GAG in mesothelioma tissue" but others believe it is about 45% of the total GAGs; compared to 28% in lung cancer." There have been four recent reports of blood and pleural fluid HA levels in mesothelioma using sensitive immunoassays'":" and one using HPLC. 1S • 4 1 In the differential diagnosis of pleural effusions using a cut-off of 100J.lg/L in pleural fluid, HA was raised in 73% of patients (11 of 15) with mesothelioma and in 23% with non-malignant inflammatory conditons but not raised in congestive heart failure." Pleural fluid concentrations of HA are about 1000 times higher than those in the blood, reflecting the synthesis of HA by pleural endothelium. Serum HA in mesothelioma has been reported to have mean levels in the range 118-750 J.lg/L, but individual levels varied greatly from 2-3800 J.lg/L. 3 6-38 Whilst serum levels are raised in advanced disease and are statistically higher than in other cancers with lung metastases, it seems that measurement of HA in pleural fluid is more likely to aid diagnosis than is serum measurement, but there is an overlap with non-malignant pleural effusions. Hyaluronic acid measurements have been made in nude mice bearing human malignant mesothelioma xenografts and its levels in the serum rose before the tumours could be detected physically. In 98 patients with asbestosis without mesothelioma the mean (± SD) serum HA was 43 ± 30 J.lg/L, indicating it had no detectable effect on HA production."
Other cancers
Serum HA levels have been found to be either normal or moderately raised in most forms of advanced cancer, including those of epithelial, muscle and lymphoid origin. 1S . 34-36.39 The mean HA was below 100J.lg/L in all these studies with occasional patients showing levels up to 1000 J.lg/L. Much higher HA levelshad been observed in cancer patients when their sera were assayed by a nephelometric method." Wilms' tumour was the only cancer apart from mesothelioma that shows very high levels of serum HA; in one series the level was > 500J.lg/L in 13 of 31 cases at diagnosis and > 5000J.lg/L in fiveof these. 42 In an independent study ofa further 33 cases of Wilms' tumour, the range was 175-280000 J.lg/L, falling to 200-830 J.lg/L after treatment. The serum HA in these patients had a wide range of molecular weights, predominantly as high molecular weight polymers.f:" In contrast, in two cases of bone metastasizing renal tumours of childhood (BMRTC), serum contained high levels of low molecular weight HA (1 -5 x 10 5 d). 44 It would appear that slight to moderate increases of serum HA can occur in many types of cancer, probably reflecting increased production. The possible role of hyaluronidase produced by tumour cells" as a mechanism for mobilizing tissue HA to increase its diffusion into tissue fluid needs further study. In this context it is of interest that local production of HA has been reported in bladder cancer" and the presence of high molecular weight species in the urine might be an indication of the behaviour of urothelial tumours. It is still uncertain whether the local concentration of HA could have immunoregulator activity in cancer.
Uraemia and haemodialysis
End stage chronic renal failure is associated with many degenerative syndromes including weight loss and musculoskeletal disorders. In patients on long term haemodialysis, arthropathy and beta-2-microglobulin amyloid deposition are well recognized syndromes. Serum HA levels are significantly correlated with serum creatinine concentration over the range of 100-2000 Jlmol creatinine/L and in 42 patients with various degrees of renal impairment HA ranged from 44-432 Jlg/L. In this preliminary study there appeared to be an association between high levels of serum HA and a poor prognosis; in contrast, patients with successful renal transplants had normal HA levels."
In a systematic study of 126 patients 'on haemodialysis that included children 73·6% had HA levels > 150Jlg/L. Serum HA levels were not related to the serum creatinine concentration, and were weakly correlated to serum /3-2microglobulin levels, an indicator of renal reserve and the duration of dialyis. The most notable feature clinically was the strong association between levels of HA > 300 Jlg/L that occurred in 31% of patients and failure to thrive on haemodialysis. Gel filtration chromatography indicated two peaks of HA in the serum, the minor peak, comprising one third of the total, was of low molecular weight and corresponded to HA found in urine which was retained in the blood due to the renal impairment (Tumey et al., unpublished data). The major peak was formed by polydisperse high molecular weight HA. The mechanism of raised serum HA in end-stage renal failure cannot be fully explained. In part it is due to failure to clear low molecular weight HA. Whether the high molecular weight material comes from overproduction or is due to impaired hepatic clearance or both is uncertain and will require parallel studies of other GAGs. Both high and low molecular weight HA are present in peritoneal dialysis fluid, whilst there is no clearance of HA by haemodialysis. It has been shown that endothelial cells endocytose HA, and the process is probably receptor mediated." It is interesting to speculate that the chronic elevation of serum HA levels in chronic haemodialysis patients, containing both the high and low molecular weight forms, could be a factor in the pathogenesis of the endothelial disorders that accompany this form of therapy.
Liver disease
Liver endothelial cells have a high affinity for HA which is cleared from the blood by receptormediated endocytosis" and studies of the regional kinetics of endogenous HA show that biodegradation of HA occurs mainly in the hepato-splanchnic region." In patients with different liver diseases, increased serum HA concentrations up to about 200 times normal have been been reported which correlate with prothrombin time and serum albumin and yglobulin concentrations." Studies of the splanchnic and renal extraction of tritium labelled HA in patients with primary biliary cirrhosis (pBC) suggest that the increased circulating HA levels found in cirrhotic patients is due to a combination of increased supply and decreased extraction from the plasma.50 More detailed analysis of 40 patients with PBC followed up 6 monthly for 40 months has demonstrated that serum HA levels steadily increase with the increasing severity of PBC. 51 On the basis of this observation it has been suggested that serial determinations may have a value in monitoring disease. In children with extra-hepatic biliary atresia serum HA was measured longitudinally and found to be of greater predictive value in diagnosing progressive liver disease than was histology." In a study comparing patients with chronic liver disease, levels were 10-1500 Jlg/L in 37 stable non-encephalopathic patients but rose to 150-5000 Jlg/L in 30 patients with encephalopathy; in acute encephalopathy the range was 300-25000 Jlg/L. 48 Recent studies on paracetamol-induced acute liver damage have shown that serum HA concentration increases to as much as 50000 Jlg/L within 72 hours of ingestion. Levels of this order were associated with grade IV coma. Recovery was associated with a rapid decline in serum HA values within 7 days of ingestion. There was no direct correlation between HA levels and standard liver function tests. 52 HA appears to be an additional marker ofliver function which does not directly correlate with other current tests. The possible advantage of HA over other tests and its clinical role are as yet unclear. With the increasing use of liver transplantation the monitoring of disease progression is becoming increasingly important and the possible role of serial HA estimations merits further study.
The rejection of human liver transplants is thought to be mediated by an attack on the HLA antigens expressed on liver endothelium, as shown by the vascular changes taken during rejection episodes." Two studies of the levels of serum HA following orthotopic liver transplant in man have been published.P':" The first study from Birmingham'? has demonstrated that rejection episodes are associated with a rise of HA (median 532 J-lg/L; range 114-1380) in 32 incidents of rejection compared to 128J-lg/L (39-700) in 20 patients with stable grafts. Chronic rejection gave higher levels than acute rejection. A second study from Cambridge has concentrated on the HA levels during the first 2 weeks after transplantation. 54 There was a progressive rise in HA with the degree of rejection and the highest levels were seen when rejection was complicated by sepsis when levels > 1000ug HA/L were usual. Very rapid rises in HA from < 100J-lg/L were observed within a few hours of the onset of acute event associated with transplantation. Following revascularization after the anhepatic phase, HA was cleared at a rate of 10-20 J-lg/L/min; but the rate of accumulation during the anhepatic phase is insufficient to account for the massive rate of rise that can accompany major technical problems in liver transplantation. 55 
Rheumatoid arthritis
The hyaluronectin affino-enzymatic assay has been used to survey 25 patients with rheumatoid arthritis (RA), 24 patients with ankylosing spondylitis (AS) and 102 controls. The mean HA was significantly higher in RA (171 ± 39 J-lg/L) than in controls (22'4 ± 1·6J-lg/L) and AS (30'3 ± 3·0 J-lg/L). Corticosteroids produced a significant fall of HA in RA. However, serum HA levels were not correlated with clinical or serological indicators of inflammatory activity. 56 Parallel studies of serum amino terminal type III procollagen and HA in RA showed they both increased in active arthritis and correlated to the clinical signs of joint inflammation.57 HA production in fibroblasts can be stimulated in vitro by tumour necrosis factor and interleukin 1 a. and (3. 58 The levels of serum HA in patients with active RA can show a highly significant increase 30 to 60 min after arising from a night's sleep and commencing normal activities. 59 In 14 patients with active arthritis the serum HA rose from 124 ± 104J-lg/L to 402 ± 232J-lg/L, the levels thereafter decreased to those seen at first.57 This is a factor that needs to be kept in mind when designing study protocols or interpreting results in RA. The clearance of HA from the blood in RA is at the same rate as in normal subjects."
Lung disease
The HA content of lung remains unchanged in normal lungs with ageing but tends to fall in emphysematous lungs." The levels of HA in bronchoalveolar lavage fluid have been studied in several lung diseases. In acute episodes of farmers' lung substantial amounts of HA and procollagen type III can be found in lavage fluid. In normal controls the HA concentration was < 15J-lg/L, rising to a mean of 547 J-lg/L (range 137-1125) in acute farmer's lung and fell to lower levels in remission (range 38-650 J-lg/L). 61 These observations indicate that excess synthesis ofHA and procollagen may be a consequence of fibroblast proliferation. During the acute attack, HA in the intestinal fluid retains water and may be a factor in impairing gas exchange. In contrast, it is only HA that is raised in the lavage fluid in acute respiratory distress syndrome in adults, procollagen was not observed. It is possible that HA is produced by the lung in response to complement-mediated stimulation." Raised levels of HA in bronchoalveolar lavage fluid have also been shown in 23 patients with sarcoidosis (median 12J-lg/L; interquartile range 7'7-28'5), there was also a significant correlation with lymphocyte content and angiotensin-converting enzyme activity, a marker of macrophage-monocyte activity." This indicates a relationship between sarcoid alveolitis and the biochemical signs of pulmonary fibroblast proliferation. A similar increase ofHA and procollagen III has been observed in lavage fluid in idiopathic pulmonary fibrosis." CONCLUSIONS Serum HA concentrations are abnormal in a number of diseases. Among these, measurement of HA in liver disease may prove to be particularly useful as HA concentrations appear to correlate with disease severity and may be helpful in judging when therapeutic intervention is required. The role of the regulation of HA synthesis in the pathogenesis of cirrhosis," the mechanism of hepatic HA clearance" and the causes of the rapid massive rise of HA concentrations in acute hepatitis still await clarification. The use ofHA measurement in monitoring treatment in liver disease, apart from in hepatic transplantation, has yet to be evaluated. In renal disease, the cause of the rise in HA concentrations in patients doing badly on haemodialysis is uncertain, though the correlation between HA concentrations and clinical state is of interest.
The improved availability of sensitive assays should simplify and enhance the investigation of HA metabolism and its clinical application both in experimental systems and in patients. The very lack of species specificity of newer assays allows them to be used in man, in experimental animals and in tissue culture. Only time will tell whether HA assays will have a place in routine clinical chemistry. The diurnal variation of serum hyluronan in health
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